Skip to content
Screener

Supernus Pharmaceuticals SUPN Business Segments — Other segment items

Similar metrics at other companies

Broadridge Financial Solutions logo
BRTotal Reportable Segments — Other segment items
$121.4M+7.5%
Iron Mountain logo
IRMTOTAL REPORTABLE SEGMENTS — Other segment items
$938.34M+13.0%
GLW
GLWTotal Reportable Segments — Other segment items
$2.77B+16.4%
CNN
CNNETotal Reportable Segments — Other segment items
$52.3M+403%
RCI Hospitality Holdings logo
RICKReportable Segments Excluding Other — Other segment items
$0-100%
Veradermics logo
MANEReportable Segment — Other segment items
-$2.63M-411%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.77B+21.8%
Enterprise value$2.63B+21.5%
P/S3.6×+0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Qelbree2,3644,413
ZURZUVAE82—
Early-stage programs and other expenses6,5653,213
Total external development program expenses27,67816,432
Internal employee-related expenses11,76010,495
Total research and development expenses39,43826,927
Other segment items(a)21,99629,017
Net loss$(2,293)$(11,827)

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's business segments — other segment items?
Supernus Pharmaceuticals (SUPN) reported business segments — other segment items of $22M in Q1 2026.
How has Supernus Pharmaceuticals's business segments — other segment items changed year-over-year?
Supernus Pharmaceuticals's business segments — other segment items decreased by 24.2% year-over-year, from $29.02M to $22M.
What is the long-term trend for Supernus Pharmaceuticals's business segments — other segment items?
Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business segments — other segment items has grown at a 10.5% compound annual growth rate (CAGR), from $67.53M to $91.14M.
What does business segments — other segment items mean?
Captures miscellaneous operational costs or income items that do not fall into standard expense categories. Monitoring this helps identify non-recurring or unique financial impacts affecting the segment's overall performance.

Ask your AI about Supernus Pharmaceuticals's business segments — other segment items.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude